Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
COR logo COR
Upturn stock ratingUpturn stock rating
COR logo

Cencora Inc. (COR)

Upturn stock ratingUpturn stock rating
$291.55
Last Close (24-hour delay)
Today's Top PicksToday’s top pick
Profit since last BUY18.08%
upturn advisory
Strong Buy
BUY since 91 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/03/2025: COR (3-star) is a STRONG-BUY. BUY since 91 days. Profits (18.08%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

17 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $321.5

Year Target Price $321.5

Analyst’s Price TargetsFor last 52 week
$321.5Target price
Low$217.25
Current$291.55
high$308.75

Analysis of Past Performance

Type Stock
Historic Profit 40%
Avg. Invested days 62
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/03/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 58.03B USD
Price to earnings Ratio 34.62
1Y Target Price 321.5
Price to earnings Ratio 34.62
1Y Target Price 321.5
Volume (30-day avg) -
Beta 0.57
52 Weeks Range 217.25 - 308.75
Updated Date 06/29/2025
52 Weeks Range 217.25 - 308.75
Updated Date 06/29/2025
Dividends yield (FY) 0.73%
Basic EPS (TTM) 8.65

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 0.55%
Operating Margin (TTM) 1.34%

Management Effectiveness

Return on Assets (TTM) 2.97%
Return on Equity (TTM) 141.78%

Valuation

Trailing PE 34.62
Forward PE 17.21
Enterprise Value 63912774477
Price to Sales(TTM) 0.19
Enterprise Value 63912774477
Price to Sales(TTM) 0.19
Enterprise Value to Revenue 0.21
Enterprise Value to EBITDA 17.2
Shares Outstanding 193823008
Shares Floating 183411289
Shares Outstanding 193823008
Shares Floating 183411289
Percent Insiders 5.31
Percent Institutions 93.97

Analyst Ratings

Rating 4.18
Target Price 321.5
Buy 1
Strong Buy 10
Buy 1
Strong Buy 10
Hold 5
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Cencora Inc.

stock logo

Company Overview

overview logo History and Background

Cencora Inc., formerly AmerisourceBergen, was founded in 2001 through the merger of Bergen Brunswig and AmeriSource Health Corporation. It has grown to become a leading global pharmaceutical distributor, providing drug distribution and related healthcare services. It has expanded through acquisitions and organic growth.

business area logo Core Business Areas

  • Pharmaceutical Distribution Services: Distributes a comprehensive range of brand-name and generic pharmaceuticals, specialty pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies.
  • Healthcare Solutions: Offers services such as inventory management, pharmacy automation, and data analytics to healthcare providers and pharmaceutical manufacturers.
  • International Healthcare Solutions: Provides pharmaceutical wholesale, distribution and commercial solutions to pharmaceutical manufacturers, pharmacies and healthcare providers in Europe and other selected geographies.

leadership logo Leadership and Structure

Steven H. Collis is the current Chairman, President and Chief Executive Officer. Cencora operates with a corporate structure divided into business segments, each managed by executive leadership, reporting to the CEO.

Top Products and Market Share

overview logo Key Offerings

  • Brand-name Pharmaceuticals: Distribution of brand-name prescription drugs. Accounts for a large portion of Cencora's revenue. Competitors include McKesson, Cardinal Health.
  • Generic Pharmaceuticals: Distribution of generic prescription drugs, offering cost-effective alternatives. Competitors include McKesson, Cardinal Health.
  • Specialty Pharmaceuticals: Distribution of specialty pharmaceuticals, including oncology and immunology drugs, which often have complex handling requirements. Competitors include McKesson, Cardinal Health, and specialty pharmacies.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical distribution industry is characterized by high volume, low margins, and intense competition. It is heavily regulated and influenced by factors such as drug pricing, healthcare reform, and supply chain security.

Positioning

Cencora is one of the top three largest pharmaceutical distributors in the US, along with McKesson and Cardinal Health. Its competitive advantages include its scale, established relationships with manufacturers and pharmacies, and comprehensive service offerings.

Total Addressable Market (TAM)

The global pharmaceutical distribution market is estimated to be hundreds of billions of dollars. Cencora is positioned to capture a significant portion through its market presence.

Upturn SWOT Analysis

Strengths

  • Large scale and market share
  • Established relationships with manufacturers and pharmacies
  • Comprehensive product and service offerings
  • Global reach

Weaknesses

  • Low profit margins
  • Reliance on a few large customers
  • Exposure to regulatory changes
  • Debt levels from Acquisitions

Opportunities

  • Growth in specialty pharmaceuticals
  • Expansion into emerging markets
  • Increased demand for healthcare services
  • Technological advancements in supply chain management

Threats

  • Drug pricing pressures
  • Increased competition
  • Supply chain disruptions
  • Changes in healthcare regulations

Competitors and Market Share

competitor logo Key Competitors

  • MCK
  • CAH

Competitive Landscape

Cencora faces intense competition from McKesson and Cardinal Health. Cencora's strengths include its scale and established relationships. Weaknesses include low profit margins and exposure to regulatory changes.

Major Acquisitions

PharmaLex

  • Year: 2020
  • Acquisition Price (USD millions): 1280
  • Strategic Rationale: Expanded Cencora's presence in specialty services and provided global regulatory expertise.

Growth Trajectory and Initiatives

Historical Growth: Cencora has grown historically through acquisitions and organic growth in the pharmaceutical distribution market. Requires data update.

Future Projections: Future growth depends on factors such as market trends, acquisitions, and new service offerings. Requires data update.

Recent Initiatives: Recent strategic initiatives may include acquisitions, partnerships, or investments in new technologies. Requires data update.

Summary

Cencora is a major player in the pharmaceutical distribution industry. Its strengths lie in its size and established relationships, but it faces challenges like low profit margins and regulatory risks. The company is well-positioned to capitalize on growth in specialty pharmaceuticals, but must navigate competitive pressures and drug pricing concerns.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Industry Reports
  • Analyst Estimates

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered financial advice. Market conditions and company performance can change, so conduct thorough research before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cencora Inc.

Exchange NYSE
Headquaters Conshohocken, PA, United States
IPO Launch date 1995-04-04
President, CEO & Director Dr. Robert P. Mauch Ph.D., PharmD
Sector Healthcare
Industry Medical Distribution
Full time employees 42000
Full time employees 42000

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.